| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DCLK1 |
| Uniprot No | O15075 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-740aa |
| 氨基酸序列 | MSFGRDMELE HFDERDKAQR YSRGSRVNGL PSPTHSAHCS FYRTRTLQTL SSEKKAKKVR FYRNGDRYFK GIVYAISPDR FRSFEALLAD LTRTLSDNVN LPQGVRTIYT IDGLKKISSL DQLVEGESYV CGSIEPFKKL EYTKNVNPNW SVNVKTTSAS RAVSSLATAK GSPSEVRENK DFIRPKLVTI IRSGVKPRKA VRILLNKKTA HSFEQVLTDI TDAIKLDSGV VKRLYTLDGK QVMCLQDFFG DDDIFIACGP EKFRYQDDFL LDESECRVVK STSYTKIASS SRRSTTKSPG PSRRSKSPAS TSSVNGTPGS QLSTPRSGKS PSPSPTSPGS LRKQRSSQHG GSSTSLASTK VCSSMDENDG PGEEVSEEGF QIPATITERY KVGRTIGDGN FAVVKECVER STAREYALKI IKKSKCRGKE HMIQNEVSIL RRVKHPNIVL LIEEMDVPTE LYLVMELVKG GDLFDAITST NKYTERDASG MLYNLASAIK YLHSLNIVHR DIKPENLLVY EHQDGSKSLK LGDFGLATIV DGPLYTVCGT PTYVAPEIIA ETGYGLKVDI WAAGVITYIL LCGFPPFRGS GDDQEVLFDQ ILMGQVDFPS PYWDNVSDSA KELITMMLLV DVDQRFSAVQ VLEHPWVNDD GLPENEHQLS VAGKIKKHFN TGPKPNSTAA GVSVIATTAL DKERQVFRRR RNQDVRSRYK AQPAPPELNS ESEDYSPSSS ETVRSPNSPF |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DCLK1重组蛋白的示例参考文献(内容为模拟示例，仅供参考)：
---
1. **标题**：*Recombinant DCLK1 Protein Expression and Its Role in Cancer Stem Cell Regulation*
**作者**：Smith A, et al.
**摘要**：研究报道了通过大肠杆菌表达系统成功纯化功能性DCLK1重组蛋白，并证明其在体外抑制结肠癌干细胞自我更新能力，提示其作为潜在治疗靶点。
2. **标题**：*Structural Characterization of DCLK1 Kinase Domain Using Recombinant Protein Technology*
**作者**：Zhang L, et al.
**摘要**：通过X射线晶体学解析DCLK1激酶结构域的三维结构，利用重组蛋白分析其ATP结合位点，为开发选择性激酶抑制剂提供结构基础。
3. **标题**：*DCLK1 Recombinant Protein as a Biomarker for Early Pancreatic Cancer Detection*
**作者**：Wang X, et al.
**摘要**：开发基于DCLK1重组蛋白的ELISA检测方法，证实其在胰腺癌患者血清中显著高表达，可能成为早期诊断的生物标志物。
4. **标题**：*Functional Analysis of DCLK1 Isoforms via Recombinant Protein Expression in Mammalian Cells*
**作者**：Johnson R, et al.
**摘要**：比较不同DCLK1剪切体重组蛋白的功能差异，发现某异构体特异性调控微管动力学，影响神经母细胞瘤细胞迁移。
---
**备注**：以上为模拟文献，实际研究需通过PubMed、Web of Science等平台检索关键词“DCLK1 recombinant protein”获取真实文献。
**Background of DCLK1 Recombinant Protein**
DCLK1 (Doublecortin-like kinase 1) is a serine/threonine kinase characterized by a unique structure containing an N-terminal doublecortin (DCX) domain and a C-terminal kinase domain. Initially identified for its role in neuronal development, DCLK1 is involved in microtubule stabilization, neuronal migration, and neurogenesis. Beyond the nervous system, DCLK1 has emerged as a critical regulator in cancer biology, particularly in tumor initiation, progression, and metastasis. It is often overexpressed in various cancers, including colorectal, pancreatic, and hepatocellular carcinomas, where it marks cancer stem cells (CSCs) and drives epithelial-mesenchymal transition (EMT), chemoresistance, and tumor recurrence.
The recombinant DCLK1 protein is engineered through molecular cloning, typically expressed in bacterial or mammalian systems to ensure proper post-translational modifications. This purified protein retains functional domains, enabling researchers to study its kinase activity, protein-protein interactions, and downstream signaling pathways (e.g., MAPK, Wnt/β-catenin). Recombinant DCLK1 is instrumental in developing targeted therapies, such as kinase inhibitors, and serves as an antigen for antibody production to detect DCLK1 in tissues or biofluids.
Recent studies highlight DCLK1's dual role as a tumor suppressor or promoter, depending on cellular context and isoform expression. Its splice variants, including short isoforms lacking the kinase domain, add complexity to its functional diversity. Research on DCLK1 recombinant proteins continues to unravel its therapeutic potential, offering insights into precision oncology and regenerative medicine strategies.
×
